VEGFA and Hypertension: In a cohort of oncologic patients treated with anti-vascular endothelial growth factor agents, we have shown that an approach based on a structured Cardio-Oncology programme with baseline evaluation and tailored recommendations for BP management resulted in a lack of association between both controlled and uncontrolled arterial hypertension at baseline and the risk of CV events (25).